Search
Displaying 211–220 of 715 for “retinitis clinical trial”
-
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
Research NewsThe company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
Beacon Stories
Lindsey Rambo once believed treatment was meant for someone else. Today, she’s the first participant in a groundbreaking gene therapy trial for LCA5—and her journey is lighting the way for what’s possible in the future of vision research.
-
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Research NewsEditas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
-
VISIONS 2024, the global conference of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Eye on the CureDr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard
Beacon StoriesDr. Léveillard helped discover and develop a gene-agnostic, cone-preserving therapy for retinitis pigmentosa that’s moving into a clinical trial.
-
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
Research News40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
.png)
